Godsey & Gibb Inc. Buys 2,041 Shares of Amgen Inc. (NASDAQ:AMGN)

Godsey & Gibb Inc. grew its position in Amgen Inc. (NASDAQ:AMGN) by 3.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 64,718 shares of the medical research company’s stock after buying an additional 2,041 shares during the period. Godsey & Gibb Inc.’s holdings in Amgen were worth $16,868,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Capital Performance Advisors LLP acquired a new stake in Amgen in the 3rd quarter valued at $25,000. Legacy Investment Solutions LLC acquired a new stake in Amgen in the 3rd quarter worth about $29,000. Hershey Financial Advisers LLC bought a new stake in shares of Amgen in the second quarter valued at approximately $30,000. Matrix Trust Co bought a new stake in shares of Amgen during the 3rd quarter valued at $36,000. Finally, Livelsberger Financial Advisory acquired a new stake in Amgen during the third quarter worth about $56,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Up 0.7 %

NASDAQ:AMGN opened at $268.94 on Thursday. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The company has a market capitalization of $144.56 billion, a P/E ratio of 34.44, a PEG ratio of 2.91 and a beta of 0.56. The firm has a fifty day simple moving average of $277.12 and a 200-day simple moving average of $308.03.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business’s revenue was up 23.2% compared to the same quarter last year. During the same period in the previous year, the business earned $4.96 earnings per share. On average, equities research analysts anticipate that Amgen Inc. will post 19.53 earnings per share for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a $2.38 dividend. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.54%. This is a boost from Amgen’s previous quarterly dividend of $2.25. Amgen’s payout ratio is currently 121.90%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on AMGN shares. Truist Financial reduced their target price on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a report on Wednesday, January 8th. Citigroup lowered their target price on Amgen from $335.00 to $310.00 in a research report on Wednesday, November 27th. Piper Sandler dropped their price target on shares of Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a research report on Thursday, January 2nd. Robert W. Baird reissued an “underperform” rating and set a $215.00 target price on shares of Amgen in a research report on Wednesday, September 25th. Finally, Royal Bank of Canada decreased their price objective on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating for the company in a research note on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $314.91.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.